dm+d
Unassigned
New Medicines
ExblifepUrinary tract infection
Information
Exblifep
New molecular entity
Allecra Therapeutics
Allecra Therapeutics
Development and Regulatory status
None
Phase III Clinical Trials
Phase III Clinical Trials
Category
Cephalosporins, carbapenems and other beta-lactams (05.01.02)
Extended-spectrum β-lactamase inhibitor
The population eligible to receive this difficult to estimate and may vary according to local resistance patterns. In 2017 and 18 there were around150000 hospital admissions for cUTIs mostly due to gram negative bacteria. Assuming 15% of these infections are resistant to currently available antibiotics, 22500 adults may be eligible for antibiotics reserved for resistant gram negative infections. [4]
Urinary tract infection
Serious, hospital acquired, gram-negative multi drug-resistant infections in combination with cefepime (a 4th generation cephalosporin antibiotic)
Intravenous